Inspire Medical's Inspire V rollout, broader approvals and clinical evidence support growth despite coding and reimbursement pressures.
Inspire Medical Systems, Inc. (INSP) Presents at Wells Fargo 2026 MedTech Innovation Spotlight Transcript
Inspire Medical's SLEEP 2026 updates spotlight new Inspire V data, remote patient tools and research supporting wider OSA therapy adoption.
| Health Care Equipment & Supplies Industry | Healthcare Sector | Timothy Herbert CEO | LSE Exchange | G52837120 CUSIP |
| US Country | 1,246 Employees | - Last Dividend | - Last Split | 3 May 2018 IPO Date |
Inspire Medical Systems, Inc. is a pioneering medical technology company that has set its sights on developing and bringing to market minimally invasive solutions specifically designed for individuals suffering from obstructive sleep apnea (OSA). With operations spanning both the United States and international markets, Inspire Medical Systems has carved out a niche in addressing the challenges faced by patients with moderate to severe OSA. Since its establishment in 2007, the company has been headquartered in Golden Valley, Minnesota, where it continues to innovate in the medical field with a keen focus on enhancing patient care through its advanced technologies.
The Inspire System stands as the flagship offering from Inspire Medical Systems, Inc., embodying the company’s commitment to innovation in the treatment of obstructive sleep apnea (OSA). This state-of-the-art neurostimulation technology provides a revolutionary and effective treatment method for patients classified with moderate to severe OSA. It operates by delivering mild stimulation to key airway muscles during sleep, thereby ensuring the airway remains open and mitigating the risks associated with OSA. The system represents a significant leap forward in OSA management, offering patients a safe alternative to traditional treatment modalities.
In its relentless pursuit of excellence, Inspire Medical Systems, Inc. is also developing a novel, groundbreaking closed-loop solution aimed at enhancing the care and management of OSA patients. This innovative approach involves a continuous monitoring system that vigilantly tracks a patient's breathing patterns throughout the night. In response to detected anomalies such as interrupted breathing, the system intelligently administers mild hypoglossal nerve stimulation. This stimulation is delicately calibrated to ensure the patient's airway remains open during sleep, thereby preventing the occurrence of apnea episodes. This closed-loop solution exemplifies the company's forward-thinking approach in harnessing technology to address the complexities of sleep apnea.